Marta
Llanos Muñoz
Part Time Assistant Professor (Health Science)


Hospital Miguel Servet
Zaragoza, EspañaPublications in collaboration with researchers from Hospital Miguel Servet (12)
2023
-
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
Nature Communications, Vol. 14, Núm. 1
2022
-
External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study
Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100
2021
-
First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis
Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231
-
Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus
Pancreatology, Vol. 21, Núm. 1, pp. 215-223
2019
-
Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 37, Núm. 28, pp. 2571-2580
2018
-
Efficacy and safety of vandetanib for patients with advanced and progressive medullary thyroid cancer (MTC) as systemic treatment beyond first-line therapy
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii476
-
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)
Oncologist, Vol. 23, Núm. 4, pp. 422-432
2013
-
Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: A Spanish, multicentre, open-label, single arm phase II study
BMC Cancer, Vol. 13
-
Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)
European Journal of Cancer, Vol. 49, Núm. 18, pp. 3780-3787
2012
-
First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Onkologie, Vol. 6, Núm. 2, pp. 96-103
-
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Oncologist, Vol. 17, Núm. 1, pp. 15-25
2003
-
Sequential doxorubicin and docetaxel as first-line treatment in metastatic breast cancer: A GEICAM-9801 phase II study
Breast Cancer Research and Treatment, Vol. 77, Núm. 1, pp. 1-8